| Literature DB >> 29662448 |
Abstract
Antioxidants present in the diet may have a significant effect on the prophylaxis and progression of various diseases associated with oxidative stress. Berries contain a range of chemical compounds with antioxidant properties, including phenolic compounds. The aim of this review article is to provide an overview of the current knowledge of such phenolic antioxidants, and to discuss whether these compounds may always be natural gifts for human health, based on both in vitro and in vivo studies. It describes the antioxidant properties of fresh berries (including aronia berries, grapes, blueberries, sea buckthorn berries, strawberries and other berries) and their various products, especially juices and wines. Some papers report that these phenolic compounds may sometimes behave like prooxidants, and sometimes demonstrate both antioxidant and prooxidant activity, while others note they do not behave the same way in vitro and in vivo. However, no unwanted or toxic effects (i.e., chemical, hematological or urinary effect) have been associated with the consumption of berries or berry juices or other extracts, especially aronia berries and aronia products in vivo, and in vitro, which may suggest that the phenolic antioxidants found in berries are natural gifts for human health. However, the phenolic compound content of berries and berry products is not always well described, and further studies are required to determine the therapeutic doses of different berry products for use in future clinical studies. Moreover, further experiments are needed to understand the beneficial effects reported so far from the mechanistic point of view. Therefore, greater attention should be paid to the development of well-controlled and high-quality clinical studies in this area.Entities:
Keywords: antioxidants; berries; health; oxidative stress; phenolic compounds
Year: 2018 PMID: 29662448 PMCID: PMC5890122 DOI: 10.3389/fphar.2018.00078
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Major types of anthocyanins, which are presented in various berries (Lee et al., 2015; Nayak et al., 2015; Wang et al., 2015; Kristo et al., 2016; Kšonžeková et al., 2016; Samoticha et al., 2017; modified).
| Berries | Type of anthocyanins | |||||
|---|---|---|---|---|---|---|
| Pelargonidin | Cyanidin | Delphinidin | Peonidin | Malvidin | Petunidin | |
| Aronia berries ( | + (major – cyaniding 3-galactoside, cyaniding 3-arabinoside; minor – cyaniding 3-glucoside; cyaniding 3-xyloside) | |||||
| Bilberries ( | + (major – cyanidin-3-galactoside; minor – cyanidin glucoside; cyanidin arabinoside) | + (minor – delphinidin arabinoside; delphinodin galactoside; delphinidin glucoside) | + (minor – peonidin glucoside) | + (minor – malvidin galactoside; malvidin arabinoside) | + (minor – petunidin glucoside) | |
| Blackcurrants ( | + (major – cyaniding 3-rutinoside; minor – cyanidin 3-glucoside) | + (major – delphinidin 3-glucoside, delphinidin 3-rutinoside) | ||||
| Blackberries ( | + (major – cyanidin-3-glucoside; minor – cyanidin-3-rutinoside, cyanidin-3-dioxalylglucoside, cyanidin-3-xyloside; cyanidin-3-malonylglucoside) | |||||
| Blueberries ( | + (major – cyaniding 3-galactoside; minor – cyaniding 3-glucoside, cyaniding 3-arabinoside) | + (major – delphinidin 3-galactoside, delphinidin 3-arabinoside; minor – delphinidin 3-glucoside) | + (minor – peonidin 3-galactoside, peonidin 3-arabinoside) | + (major – malvidin 3-galactoside, malvidin 3-arabinoside; minor – malvidin 3-glucoside) | + (major – petunidin 3-galactoside, petunidin 3-arabinoside; minor – petunidin 3-glucoside) | |
| Cranberries ( | + (major – cyanidin 3-galactoside, cyanidin 3-arabinoside) | + (major – peonidin 3-galactoside, peonidin 3-arabinoside) | ||||
| Elderberries ( | + (major – cyanidin-3-sambubioside; minor-cyanidin-3-glucoside, cyanidin 3,5-diglucoside, cyanidin-3-sambubioside-5-glucoside) | |||||
| Grapes ( | + | + | + | + | + | + |
| Raspberries ( | + | |||||
| Strawberries ( | + (major – pelargonidin-3-glucoseide) | + (minor – cyanidin-3-glucoside) | ||||
The concentration of total phenolic compounds and anthocyanins in different berries and their products (Olas et al., 2008; Daskalova et al., 2015; Lee et al., 2015).
| Berries and their products | Phenolic compounds | Anthocyanins |
|---|---|---|
| Aronia ( | 2080 mg/100 g fruits | 240 mg/100 g fruits (frozen) |
| 280 mg/100 g fruits (dried) | ||
| Aronia ( | 309.6 mg/g of extract | 110.7 mg/g of extract |
| Aronia ( | 4772.2 mg/l | 3529.1 mg/l |
| Bilberries ( | 181–585 mg/100 g fruits | |
| Blackberries ( | 248 mg/100 g fruits | 949.4 mg/100 g dw |
| Blueberries ( | 525 mg/100 g fruits | 1562.2 mg/100 g dw |
| Blackcurrants ( | 560 mg/100 fruits | 1741.6 mg/100 g dw |
| Cranberries ( | 120–315 mg/100 g fruits | |
| Grape ( | 500 mg/g of extract | |
| Red wines | 1000 – 4000 mg/l | 2.8 mg/l |
| White wines | about 250 mg/l | |
| Raspberries ( | 126 mg/100 g fruits | |
| Sea buckthorn ( | 260 – 490 mg/100 g FW | |
| Strawberries ( | 225 mg/100 g fruits | 60 – 80 g per 100 g FW |
Antioxidant capacity [measured by oxygen radical absorbing capacity (ORAC) or by Trolox equivalent capacity (TEAC)] of various fresh berries and berry juice [Kulling and Rawel, 2008; modified].
| Berries | ORAC (μmol of Trolox equivalents/gram fresh weight) |
|---|---|
| Aronia berries | 159.2 ± 1.0 |
| Blackberries | 55.7 ± 14.7 |
| Blackcurrants | 56.7 ± 13.5 |
| Strawberries | 20.6 ± 2.3 |
| Cranberries | 10.4 ± 1.9 |
| Red grapes | 7.4 ± 0.5 |
| White grape | 4.5 ± 1.9 |
| Aronia juice | 65 - 70 |
| Blueberry juice | 13.3 – 17.1 |
| Cranberry juice | 6.7 – 14.8 |
The effect of different berries on the level of various biomarkers of oxidative stress.
| Berries | Different biomarkers of oxidative stress |
|---|---|
| Aronia berries | |
| Model of hyperhomocysteinemia, human blood platelets, concentration of Aronox (containing phenolic compounds: 309.8 mg/g of extract): 2.5 – 10 μg/ml ( | |
| Human blood platelets, healthy subjects, concentration of Aronox (containing phenolic compounds: 309.8 mg/g of extract): 5–50 μg/ml ( | |
| Human blood platelets, patients with cardiovascular risk factors, concentration of Aronox (containing phenolic compounds: 309.8 mg/g of extract): 1–100 μg/ml ( | |
| Human blood platelets, healthy subjects, patients with invasive breast cancer (before/after surgery and after I – IV phase of chemotherapy) and patients with benign breast diseases, concentration of Aronox (containing phenolic compounds: 309.8 mg/g of extract): 50 μg/ml ( | |
| Human blood platelets, healthy subjects, concentration of Aronox (containing phenolic compounds: 309.8 mg/g of extract): 1–100 μg/ml ( | |
| Human plasma, healthy subjects, patients with invasive breast cancer (before/after surgery and after I – IV phase of chemotherapy), concentration of Aronox (containing phenolic compounds: 309.8 mg/g of extract): 50 μg/ml ( | |
| Human blood platelets, healthy subjects, patients with benign breast diseases, patients with invasive breast cancer, concentration of Aronox (containing phenolic compounds: 309.8 mg/g of extract): 50 μg/ml ( | |
| Human plasma, healthy subjects, patients with invasive breast cancer (before/after surgery and after I – IV phase of chemotherapy), concentration of Aronox (containing phenolic compounds: 309.8 mg/g of extract): 50 μg/ml ( | |
| Human blood platelets, healthy subjects, patients with benign breast diseases, patients with invasive breast cancer, concentration of Aronox (containing phenolic compounds: 309.8 mg/g of extract): 50 μg/ml ( | |
| Human plasma, healthy subjects, patients with invasive breast cancer (before/after surgery and after I – IV phase of chemotherapy), concentration of Aronox (containing phenolic compounds: 309.8 mg/g of extract): 50 μg/ml ( | |
| Rat hepatocytes treated with carbon tetrachloride and tert-butyl hydroperoxide, aronia juice (phenolic compounds: 546.1 mg as GAE/100 ml): 5–100 μg/ml ( | |
| Human plasma, healthy subjects, patients with invasive breast cancer (before/after surgery and after I – IV phase of chemotherapy), concentration of Aronox (containing phenolic compounds: 309.8 mg/g of extract): 50 μg/ml ( | |
| Human plasma, healthy subjects, patients with invasive breast cancer (before/after surgery and after I – IV phase of chemotherapy) and patients with benign diseases, concentration of Aronox (containing phenolic compounds: 309.8 mg/g of extract): 50 μg/ml ( | |
| Rat hepatocytes treated with carbon tetrachloride and tert-butyl hydroperoxide, aronia juice (phenolic compounds: 546.1 mg as GAE/100 ml): 5–100 μg/ml ( | |
| Human blood platelets, healthy subjects, patients with benign breast diseases, patients with invasive breast cancer, concentration of Aronox (containing phenolic compounds: 309.8 mg/g of extract): 50 μg/ml ( | |
| Human blood platelets, healthy subjects, concentration of Aronox (containing phenolic compounds: 309.8 mg/g of extract): 5 – 100 μg/ml ( | |
| Grapes | |
| Model of hyperhomocysteinemia | |
| Human blood platelets, healthy subjects, concentration of the phenolic fraction of seed (containing phenolic compounds: 500 mg/g of extract): 1.25 – 50 μg/ml ( | |
| Rat hepatocytes treated with adriomycin, extract of phenolic compounds from defatted milled grape seeds: 2.5 – 25 μg/ml ( | |
| Swine erythrocytes, extract from grape seeds (over 90% condensed tannins): 7.5 – 30 μg/ml ( | |
| Bovine spermatozoa, polyphenolic-rich grape pomace extract: 1–5 μg/ml ( | |
| Rat hepatocytes treated with adriomycin, extract of phenolic compounds from defatted milled grape seeds: 2.5 – 25 μg/ml ( | |
| Human blood platelets, healthy subjects, concentration of the phenolic fraction of seed (containing phenolic compounds: 500 mg/g of extract): 5 – 100 μg/ml ( | |
| Rat hepatocytes treated with adriomycin, extract of phenolic compounds from defatted milled grape seeds: 2.5 – 25 μg/ml ( | |
| Swine erythrocytes, extract from grape seeds (over 90% condensed tannins): 7.5 – 30 μg/ml ( | |
| Human blood platelets, healthy subjects, concentration of the phenolic fraction of seed (containing phenolic compounds: 500 mg/g of extract): 5 – 100 μg/ml ( | |
| Human blood platelets, healthy subjects, concentration of the phenolic fraction of seed (containing phenolic compounds: 500 mg/g of extract): 5 – 100 μg/ml ( | |
| Bluescript-SH + plasmid DNA exposed to UV plus H2O2 or to UV plus H2O2 in the presence grape pomace extract (containing phenolic compounds 648 mg gallic acid/g extract): 100–1600 μg/ml ( | |
| Sea buckthorn berries | |
| Human blood platelets, healthy subjects, concentration of the phenolic fraction of berry (dominant compounds in this fraction – flavonoids: 214.04 mg/g): 0.5–50 μg/ml ( | |
| Human blood platelets and human plasma, healthy subjects, concentration of the phenolic fraction of berry (dominant compounds in this fraction – flavonoids: 214.04 mg/g): 0.5–50 μg/ml ( | |
| Human plasma, healthy subjects, concentration of the phenolic fraction of berry (dominant compounds in this fraction – flavonoids: 214.04 mg/g): 0.5–50 μg/ml ( | |
| Bilberries + lingonberries + black currants | |
| Human plasma, healthy subjects, mix of berries (bilberries, lingonberries and black currants; 80 g of each, in the short-term) or 100 g portion of deep-frozen berries (bilberries, lingonberries and black currants) daily for 8 weeks ( | |
| Bilberries + red grapes | |
| human plasma and erythrocytes, healthy subjects, mixture of red grapes and bilberries (80:20), 300 ml mixture daily for 2 weeks ( | |
| Human plasma, healthy subjects, mixture of red grapes and bilberries (80:20), 300 ml mixture daily for 2 weeks ( | |
| Human plasma and urine, healthy subjects, mixture of red grapes and bilberries (80:20), 300 ml mixture daily for 2 weeks ( | |
| Blackberries + black currants + sour cherries + aronia berries + red grapes | |
| Human peripheral blood mononuclear cells, healthy subjects, mixed fruit juice (red grape (57%), blackberry juice (18%), sour cherry juice (9%), black currant juice (9%), and aronia berry juice (7%), containing 1753 mg of phenolic compounds/l catechin equivalents and 197.9 mg of anthocyanins/l cyaniding-3-glucoside equivalents), 700 ml juice daily for 9 weeks ( | |
| Human blood, healthy subjects, mixed fruit juice (red grape (57%), blackberry juice (18%), sour cherry juice (9%), black currant juice (9%), and aronia berry juice (7%), containing 1753 mg of phenolic compounds/l catechin equivalents and 197.9 mg of anthocyanins/l cyaniding-3-glucoside equivalents), 700 ml juice daily for 9 weeks ( | |
| Human plasma and urine, healthy subjects, mixed fruit juice (red grape (57%), blackberry juice (18%), sour cherry juice (9%), black currant juice (9%), and aronia berry juice (7%), containing 1753 mg of phenolic compounds/l catechin equivalents and 197.9 mg of anthocyanins/l cyaniding-3-glucoside equivalents), 700 ml juice daily for 9 weeks ( | |
| Aronia berries | |
| Rat hepatocytes, rats treated with N-nitrosodiethylamine (150 mg/kg) and carbon tetrachloride (2 ml/kg), aronia juice (10 ml/kg/day) for 4 weeks ( | |
| Rat plasma, liver, rates treated with carbon tetrachloride, aronia juice (5, 10, and 20 ml/kg) daily for 2 – 4 days ( | |
| Rat hepatocytes, rats treated with | |
| Human hemolysates, men with blood cholesterol concentration: 205–250 mg/dl, 240 mg of anthocyanins (as Aronox) daily for 30 days ( | |
| Rat hepatocytes, rats treated with carbon tetrachloride (2 ml/kg), aronia juice (10 ml/kg/day) for 4 weeks ( | |
| Rat plasma, rats treated with | |
| Rat blood leukocytes, rats treated with N-nitrosodiethylamine (150 mg/kg), aronia juice (10 ml/kg/day) for 4 weeks ( | |
| Bayberries | |
| Human plasma, young adults with features of non-alcoholic fatty liver disease, 250 ml bayberries juice (containing 270.2 mg phenolic compounds/100 ml and 83.5 mg anthocyanins/100 ml), twice daily for 4 weeks ( | |
| Bilberries | |
| Human plasma, subjects at increased risk of cardiovascular disease, 330 ml bilberry juice daily for 4 weeks ( | |
| Blackcurrants | |
| Human plasma, healthy subjects, 250 ml blackcurrant juice (containing 27.3 mg phenolic compounds/100 ml and 4 mg anthocyanins/100 ml) 4 times a day for 6 weeks ( | |
| Blueberries | |
| human plasma, healthy subjects, blueberries, 100 g freeze-dried berries with a high-fat meal ( | |
| Human plasma, chronic smokers, fresh blueberries (250 g, daily), for 3 weeks ( | |
| Human plasma, obese men and women with metabolic syndrome, blueberries (50 g freeze-dried blueberries and about 350 g fresh blueberries) daily for 8 weeks ( | |
| Human plasma, postmenopausal women with pre- and stage 1-hypertnsion, 22 g freeze-dried blueberry powder (containing 844.6 mg phenolic compounds) daily for 8 weeks ( | |
| Human plasma, healthy smokers, frozen blueberries (300 g, containing 309 mg of anthocyanins, about 856 mg of phenolic acids, 30 mg of chlorogenic acid), daily for week ( | |
| Human peripheral blood mononuclear cells, healthy smokers, frozen blueberries (300 g, containing 309 mg of anthocyanins, about 856 mg of phenolic acids, 30 mg of chlorogenic acid), daily for week ( | |
| Cranberries | |
| Human plasma, healthy subjects, cranberry juice ( | |
| Human plasma, healthy subjects, cranberry juice (7 ml/kg body weight per day), for 2 weeks ( | |
| Human plasma, healthy subjects, cranberry juice (7 ml/kg body weight per day), for 2 weeks ( | |
| Human plasma, patients with the metabolic syndrome, cranberry juice (0.7 l/day, containing 0.4 mg folic acid) for 60 days ( | |
| Human plasma, patients with the metabolic syndrome, cranberry juice (0.7 l/day, containing 0.4 mg folic acid) for 60 days ( | |
| Human blood, plasma, red blood cells and urine, healthy subjects, cranberry juice (750 ml/day, containing about 1136 mg of phenolic compounds/l GAE, about 2.8 mg of anthocyanins/l), for 2 weeks ( | |
| Elderberries | |
| Human plasma, healthy subject, elderberry juice (200, 300, or 400 ml, containing 361, 541, and 722 mg anthocyanins, respectively) daily for 2 weeks ( | |
| Human plasma, healthy subjects, elderberry juice (400 mg, containing 10% anthocyanins) daily for 2 weeks ( | |
| Grapes | |
| Rat liver, rat received irradiation as 8 Gy whole body irradiation, 100 g grape seed extract (total phenolic compounds – 573.5 mg GAE/g) daily for 1 week ( | |
| rat lever and kidney, lead induced oxidative stress in rats, 400 mg hydroalcoholic extract/kg daily for 30 days ( | |
| Cardiac tissues of rats, pancreas tissues of rats, rats were exposed to 5 Gy, grape seed extract (100 mg/kg body weight) daily for 2 weeks ( | |
| Rat plasma, pregnant rats, hydroethanolic red grapes extract, 3 × 30 mg/kg body weight daily for 2 weeks ( | |
| Wistar rats plasma, a single dose of 300 mg kg-1 body weight of grape pomace extract (containing phenolic compounds 648 mg gallic acid/g extract) ( | |
| Rat liver, rat received irradiation as 8 Gy whole body irradiation, 100 g grape seed extract (total phenolic compounds – 573.5 mg GAE/g) daily for 1 week ( | |
| Rat lever and kidney, lead induced oxidative stress in rats, 400 mg hydroalcoholic extract/kg daily for 30 days ( | |
| Cardiac tissues of rats, pancreas tissues of rats, rats were exposed to 5 Gy, grape seed extract (100 mg/kg body weight) daily for 2 weeks ( | |
| Wistar rats, gastrocnemius muscle, heart, a single dose of 300 mg kg-1 body weight of grape pomace extract (containing phenolic compounds 648 mg gallic acid/g extract) ( | |
| Wistar rats plasma, erythrocytes, gastrocnemius muscle, heart, liver, a single dose of 300 mg kg-1 body weight of grape pomace extract (containing phenolic compounds 648 mg gallic acid/g extract) ( | |
| Wistar rats plasma, erythrocytes, heart, a single dose of 300 mg kg-1 body weight of grape pomace extract (containing phenolic compounds 648 mg gallic acid/g extract) ( | |
| Wistar rats erythrocytes, liver, a single dose of 300 mg kg-1 body weight of grape pomace extract (containing phenolic compounds 648 mg gallic acid/g extract) ( | |
| Wistar rats erythrocytes, liver, a single dose of 300 mg kg-1 body weight of grape pomace extract (containing phenolic compounds 648 mg gallic acid/g extract) ( | |
| Wistar rats, gastrocnemius muscle, liver, a single dose of 300 mg kg-1 body weight of grape pomace extract (containing phenolic compounds 648 mg gallic acid/g extract) ( | |
| Wistar rats, gastrocnemius muscle, liver, a single dose of 300 mg kg-1 body weight of grape pomace extract (containing phenolic compounds 648 mg gallic acid/g extract) ( | |
| Wistar rats, gastrocnemius muscle, heart, a single dose of 300 mg kg-1 body weight of grape pomace extract (containing phenolic compounds 648 mg gallic acid/g extract) ( | |
| Wistar rats, gastrocnemius muscle, a single dose of 300 mg kg-1 body weight of grape pomace extract (containing phenolic compounds 648 mg gallic acid/g extract) ( | |
| Raspberries | |
| Human urine, Barrett’s esophagus patients, lyophilized raspberries [32 g (female) or 45 g (male)] daily ( | |
| Human plasma, healthy subjects, 30 g of freeze-dried raspberries (total phenolic compounds – 1.05 g/100 g of freeze dried berries) daily for 4 weeks ( | |
| Human plasma, healthy subjects, 30 g of freeze-dried raspberries (total phenolic compounds – 1.05 g/100 g of freeze dried berries) daily for 4 weeks ( | |
| Sea buckthorn berries | |
| Human plasma, healthy subjects, 300 ml sea buckthorn juice (containing 1182 mg flavonoids/l) daily for 8 weeks ( | |
| Strawberries | |
| Human plasma, women with metabolic syndrome, 2 cups of strawberry drink per day (each cup had 25 g of freeze-dried strawberry powder, containing about 1000 mg of phenolic compounds) for 4 weeks ( | |
| Human plasma, hyperlipidemic subjects, fresh strawberries (454 g) daily for 4 weeks ( | |
| Rat gastric, 40 mg/day/kg body weight of strawberry crude extract for 10 days ( | |
| Human plasma, subjects with type 2 diabetes, 2 cups of freeze-dried strawberry (50 g of freeze-dried strawberry is equivalent to 500 g of fresh strawberries) daily for 6 weeks ( | |
| Rat plasma and liver tissue, 25 g strawberries daily for 2 months ( | |
| Plasma, adults with abdominal adiposity and elevated serum lipids, freeze-dried strawberries (25 – 50 g/day) for 12 weeks ( | |
| Rat gastric, 40 mg/day/kg body weight of strawberry crude extract for 10 days ( | |
| Rat plasma and liver tissue, 25 g strawberries daily for 2 months ( | |
| Human plasma, subjects with type 2 diabetes, 2 cups of freeze-dried strawberry (50 g of freeze-dried strawberry is equivalent to 500 g of fresh strawberries) daily for 6 weeks ( | |
| Human plasma, healthy subjects, daily consumption of strawberries, for 2 weeks ( | |
| Wild blueberries | |
| Human plasma, healthy subjects, wild blueberries, 100 g freeze-dried berries daily for 7 days with a high-fat meal ( | |
| Human blood mononuclear cells, subjects with risk factors for cardiovascular disease, wild blueberry powder drink (one portion (25 g) containing 0.4 g anthocyanins and 127.5 g chlorogenic acid), daily for 6 weeks ( | |
| Rat plasma, wild blueberry powder, daily for 4 or 8 weeks ( | |